Background: Involvement of risk-organs (RO+) in Langerhans cell histiocytosis (LCH) and inadequate early response identifies patients at high risk for relapse and mortality requiring intensive salvage therapy including stem cell transplant, adding cost and toxicity. To mitigate this, we used a standard induction, augmented with metronomic etoposide, and prolonged maintenancesimilarly augmented for RO+, and retrospectively analyzed its impact. Maintenance was 3-weekly vinblastine and 5-day prednisolone pulses, daily 6-mercaptopurine (60 mg/m 2 ) and weekly methotrexate (15 mg/m 2 ) for 18 and 9 months for RO+ and MSRO−, respectively. RO+ also received oral etoposide (50 mg/m 2 ) for 21 of every 28-day cycle for the first year.
INTRODUCTION
Histiocytic disorders in children consist of a broad group of disorders owing to their common origin from the activated cells of the monocyteAbbreviations: 6-MP, 6-mercaptopurine; AD, active disease; allo-SCT, allogeneic stem cell transplant; EFS, event free survival; LCH, Langerhans cell histiocytosis; MFB, multifocal bone disease; MS, multisystem; NAD, no active disease; OS, overall survival; RO−, without risk organ involvement; RO−(L), risk organ not involved (lung); RO+, risk organ involvement; SS, single site; TR&A, treatment refusal and abandonment; Vbl, vinblastine macrophage system, which resemble the histiocytes. The varied manifestations of disease depend on the degree of involvement of various organ systems. 1 Langerhans cell histiocytosis (LCH) was formerly known as histiocytosis X. It included eosinophilic granuloma, LettererSiwe disease, and Hand-Schuller-Christian disease. 2 Since then, there has been unprecedented progress in the understanding of this enigmatic disease over the past few decades by means of collaborative trials, notably the LCH trials by the Histiocyte Study Groups, and large single institutional studies. [3] [4] [5] [6] [7] [8] Uniformity and consensus has evolved in diagnostic criteria, the concept of variable behavior being stratified by the number of systems involved, and enhanced risk for mortality by type of organ systems involved. This has led to risk-stratification of the disease for the purpose of treatment, with early response to initial treatment being brought in as the next stratification point to separate those who would need further intensification versus those who would go on to a maintenance phase.
Etoposide is an effective drug in LCH, but its use was discontinued in subsequent LCH trials after LCH-II, given its secondary malignancy potential and no added benefit over the alternate backbone regimen of vinblastine (Vbl) and steroids. However, long-term follow-ups of those cohorts showed that those who received etoposide had longer and more durable remissions. 9 A prolonged maintenance with addition of 6-mercaptopurine (6-MP) also contributed to lower reactivation rates. 7 In developing countries like India, patients can afford first-line therapy for LCH. However, salvage options with toxic chemotherapy and hematopoietic stem cell transplant remain beyond reach of most.
Therefore, strategies to decrease disease progression at reassessment time points and reduce recurrences are likelier to ensure treatment completion in most patients, thereby improving chances of survival.
This led us to persist with a strategy of augmented induction and similarly augmented and prolonged maintenance especially in the context of risk organ involvement (RO+). A regimen with metronomic oral etoposide for RO+ in induction and continuation phase with prolonged maintenance including methotrexate was devised to reduce the need for salvage. A retrospective analysis was conducted for patients uniformly treated with this strategy at our center-a large tertiary cancer care apex institution in India.
AIMS AND OBJECTIVES
Patients accrued over a 5-year period by a uniform protocol were analyzed retrospectively with the aim of assessing the effectiveness of the strategy in inducing early responses and its impact on outcome measures. The objectives were to assess early response at 6 weeks by imaging modalities, overall survival (OS), and event free survival (EFS). Secondary objectives were to study the clinical profile of our cases. Institutional ethics committee approval was taken for this retrospective study. 
MATERIALS AND METHODS

LCH
RESULTS
Epidemiological and clinical profile
Fifty patients with LCH were registered. Male to female ratio was 2.5:1.
Median age at diagnosis was 36 months (range 4-189 months). SS, MS-RO−, and RO+ patients were 29 (58%), 12 (24%), and nine (18%), respectively. Lung, bone marrow, liver, and spleen involvement were seen in seven (14%), four (8%), three (6%), and four (8%) patients, respectively. Of the seven patients with lung involvement, six had no other risk organ involvement. They have now been grouped as RO− as per current understanding. However, as they were treated more intensely in a manner similar to the RO+ patients, they have now been analyzed separately. Baseline evaluations for disease extent and stratification were done mostly by nuclear imaging techniques (positron emission tomography scan and bone scan, together comprising 74%), followed by conventional techniques of radiology (skeletal survey, computerized tomography scan, and ultrasonography), usually as complementary studies. Response evaluations were done by similar imaging methods as those at diagnosis in all evaluable cases.
Evaluable patients for response and outcome
Of the 50 patients who started therapy, data for four were not available (three RO− and one SS), as they were lost to follow-up before the first re-evaluation point at 6 weeks. They have been excluded for the pur- (Table 1) . In one patient, re-evaluation was missed at 12 weeks as well, but NAD was achieved by the end of 25 weeks of treatment. The profile and outcome of all 50 patients is given individually in Supplementary Table S1. One patient had response evaluation only at the end of 6 months treatment and was NAD at that time. NAD, no active disease; AD-B, active disease better; AD-I, active disease intermediate; AD-W, active disease worse; MS RO−, multisystem without risk organ involvement; RO+, risk organ involvement.
Relapse/ reactivation
F I G U R E 2
Outcome analysis: event free survival (n = 43), RO+ patients (n = 9, in green), versus RO− and SS patients (n = 34, in blue) SS disease. The patient who had RO+ relapse was given augmented reinduction (with additional etoposide) and the other patients were given the same low risk re-induction. All the three relapsed patients achieved NAD after re-induction and were alive at last follow-up. On a routine telephonic follow-up, one RO− (L) who was in sustained remission at last follow-up at 24 months was reported to have died at his village of unrelated cause 2 months later. No cases of marrow failure, myelodysplasia, or leukemia were seen on follow-up.
Lung involvement
Six patients were grouped for treatment along with RO+ when the lung was the solitary risk organ involvement. Three of these were lost to follow-up and nonevaluable. Of the remaining patients, two are in sustained remission after initial good response, and the third accounted for the only mortality while off treatment and in remission at last follow-up, as already detailed above.
Outcomes
Median duration of follow-up in our study was 39 months (Range 8-84 months). EFS at 5 years for MSRO− and SS patients was 85.6%, while it was 100% for RO+ patients. OS at 2 years and projected at 5 years were 100% for RO+, RO−, and SS patients (Figure 2 ). The only mortality, albeit of unrelated causes, while in remission, occurred in an RO−(L) patient who, as per our algorithm, had been treated with the more intense protocol of RO+ patients. Thus, 5-year OS for the entire cohort of 46 patients, which included the 3 RO−(L) patients, was 97%.
DISCUSSION
Over time, diagnostic criteria have evolved and risk stratification for Various studies have shown the significant benefit of intensified therapy in high risk patients, notably the LCH trials by the Histiocyte Study Groups, and large single institutional studies. [3] [4] [5] [6] [7] [8] However, RO+ patients have historically had poor outcomes, though survival rates have improved to 84% with contemporary protocols. LCH-I found a 6-month induction, with etoposide or Vbl with pulsed steroids being equivalent. LCH-II had also used etoposide for RO+ with or without an intensified 6-week induction of Vbl and steroids in a randomized fashion and found them equivalent, both being superior to LCH-I in inducing early responses. 9 Earlier, etoposide had been shown to be effective in recurrent LCH as well. 12, 13 Thereafter, it was rejected as a strategy for further LCH trials as it was thought that the same benefit could be achieved by intensified two-drug induction and a prolonged maintenance, without the leukemogenic potential risk attributed to etoposide from known literature. 7 Lack of early response at 6 weeks also became the cornerstone for further therapy, with re-induction and early salvage therapy being brought up to 6 or 12 weeks to counterbalance a two-drug induction. For those still refractory, newer agents can be tried before resorting to allogeneic stem cell transplant (allo-SCT); however, all these options involve considerable expenses, toxicities, or both. Subsequently, long-term follow-up studies of the LCH-II trial showed better OS for the group receiving etoposide in the intensified induction. 9 In our group, we retained etoposide in the induction regimen, due to its proven efficacy and the inability of most of our patients to undergo aggressive salvage chemotherapy options including allo-SCT.
Unlike the LCH trials where the drug was given intravenously, we used the oral route given our experience in similar metronomic dosing for myeloid and other malignancies. 14 Metronomic dosing and therapy is increasingly seen as an alternative to aggressive maximum tolerated dose based conventional therapy, which is able to effectively address tumor angiogenesis and exert immunomodulatory effects on the tumor microenvironment in addition to the mitotic activity of the tumor itself, and its use is a viable alternative for low and middle income countries (LMIC). 14 The tolerance of the regimen used for etoposide in our protocol has been well established by other groups, and in ours, where we used it for many patients unable to afford conventional therapy or till such time when funds could be arranged for the same. [15] [16] [17] [18] [19] [20] Our group had also previously published the use of similarly scheduled etoposide in LCH, albeit as a single agent and despite the dose being twice that of the current protocol, it was found to be well tolerated. 21 Another issue faced in a low and middle income country like ours is treatment refusal and abandonment (TR&A) due to social and economic reasons. Four of our patients abandoned treatment, three of them in the period up till 2011. These factors may also account for lower representation of RO+ patients in our cohort, as some patients with more aggressive forms of the disease may not be approaching a tertiary center like ours. Since 2010, our group has put several measures in place to reduce TR&A rates, including arranging funding for treatment, accommodation, nutrition, and other issues through an elaborate team of social workers and other support staff. This served to bring TR&A rates down from 25 to 30% before 2009, to consistently below 5% by 2012 (internal data, submitted for publication elsewhere). This also benefitted LCH patients. A big factor was the low cost of the protocol; without the need for expensive salvage regimens, the entire therapy for an RO+ patient was completed within less than an equivalent of USD 1000.
By using etoposide in the current protocol, we have consistently managed to achieve NAD status by 12 weeks in up-front and relapse settings without any disease-or treatment-related mortality over an extended follow-up period. However, secondary leukemogenesis remains a potential risk. This risk needs to be offset against the significant mortality of RO+ LCH, as even LCH-III has reported a 5-year OS of 84% in this subgroup. 7 Also, a detailed analysis of secondary leukemogenesis in LCH patients exposed to etoposide suggests the risk may be higher only in Latino origin patients who showed a propensity for developing promyelocytic leukemia. 22 There are also data to suggest that prolonged oral low dose etoposide is nongenotoxic, as compared to short exposure to etoposide in high concentrations following intravenous therapy. 23 LCH-I and LCH-II had reactivation rates of around 50% in contrast to the earlier Deutsche Arbeitsgemein-schaft fur LeukamieforschungHistiocytosis X trials, where reactivation rates were only 29%, probably due to longer duration of therapy in the latter. LCH-III demonstrated a clear advantage in low-risk patients receiving maintenance for 1 year, compared to those receiving it for 6 months, with reactivation rates of 37% and 54%, respectively. High risk patients benefitted from longer maintenance as well, with reactivation rates between 25 and 29%; however, addition of methotrexate did not give any additional benefit. 3, 4, 7 In comparison, our reactivation rates were only 6.6%
at a median of 32 months, supporting the view that therapy prolongation and intensification would have a role in reducing reactivations.
However, the small size of our study, done at a single center, makes our data only indicative, and not comparable. Also, it bears mention that as the proportion of RO+ patients in our study were lower than those reported in larger trials, they reflect the outcome of nonrisk disease more broadly, and to that extent reaffirm the efficacy of the LCH III strategy in treating these patients.
CONCLUSIONS
At our institute, the RO+ patients receiving intensified induction chemotherapy with oral etoposide administered in a metronomic schedule showed good response rates with no significant toxicity.
Prolonging maintenance with addition of 6-MP and methotrexate also had an impact on reducing reactivation rates. Patients had excellent survival rates across all risk groups, and reactivations could also be easily managed. Our strategy, born from a pressing need to avoid toxic and expensive salvage strategies, was extremely successful in achieving its purpose, while also being economical. There is a need to explore these strategies in a multicenter setting with larger cohorts to establish their correctness and adequacy.
